Given the important pathologic roles that CXCL12/CXCR4 axis play in NSCLC and given the urgent need for novel therapeutics for this devastating disease, it appears that now is the time to move forward and attempt to incorporate CXCR4 inhibitors in novel immune-based lung cancer therapeutic protocols. This evidence concerns the gene CXCL12 and lung carcinoma.